All In Biotech

NDA 020385 · Pfizer INC

Nicotrol

Nicotine · Nasal · Cholinergic Nicotinic Agonist

Last checked: Nov 19, 2026Latest source record: May 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Mar 22, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

911

103 Phase 3, 74 recruiting

FAERS reports

17,295

11,425 serious, 1,618 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2025.

INDICATIONS AND USAGE NICOTROL NS is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms. NICOTROL NS therapy should be used as a part of a comprehensive behavioral smoking cessation program. The safety and efficacy of the continued use of NICOTROL NS for periods longer than 6 months have not been adequately studied and such use is not recommended.

Mechanism: Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of nicotine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses, the stimulant effects predominate while at high doses the reward effects predominate. Intermittent...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 22, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • NICOTROL · NICOTINE 0.5MG/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine" as an intervention, any sponsor and status, largest first.

All 911 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,091
  • nausea1,137
  • headache789
  • overdose780
  • foetal exposure during pregnancy755
  • nicotine dependence741
  • product adhesion issue734
  • dyspnoea683
  • treatment noncompliance672
  • malaise671
  • pain632
  • dizziness629

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004240
2005233
2006331
2007445
2008329
2009455
2010758
2011701
2012792
2013491
2014625
2015713
2016854
2017750
20182,020
20191,265
20201,203
2021934
2022909
2023896
2024902
2025847
2026602

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nicotrol (Nicotine)

2024 spending

$740K

Beneficiaries

824

1,297 claims

Per beneficiary

$899

$2.94 per unit

View as table
YearSpending
2020$15,638,110
2021$17,840,443
2022$18,560,286
2023$15,332,026
2024$740,371

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,065 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.